This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment…

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD

~Estimated

~$10 – $8,750

Adverum Biotechnologies, Inc.NCT07482176

Phase 2

Evaluation of the Safety and Tolerability of Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy in the Second (Contralateral) Eye of Participants With Bilateral Neovascular Age-related Macular Degeneration.

The purpose of this study is to evaluate safety, effectiveness and durability of a gene therapy called Ixo-vec (Ixoberogene soroparvovec) when administered to …

Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD

~Estimated

~$10 – $8,750

Adverum Biotechnologies, Inc.NCT07630649